European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Overactive bladder: onabotulinumtoxinA as treatment

Published Sun, 1 Mar 2015
E CourseLUTSOveractive Bladder OAB
OrganiserEuropean School of Urology
CME2
DurationApprox. 120 minutes

Online course on effective management of pathophysiological conditions affecting the lower urinary tract (overactive bladder and neurogenic detrusor overactivity)

COURSE CONTENT:

Module 1. OnabotulinumtoxinA clinical data

Chapter 1: What is onabotulinumtoxinA?

Chapter 2: How does onabotulinumtoxinAwork in the bladder?

Chapter 3: Evidence for onabotulinumtoxinA in OAB

Chapter 4: Evidence for onabotulinumtoxinA in NDO

Module 2. OnabotulinumtoxinA in practice

Chapter 1: Practical considerations before treatment

Chapter 2: Administration in OAB

Chapter 3: Administration in NDT

Chapter 4: Aftercare and re-treatment

Chapter 5: A fully informed patient

Chapter 6: Setting up an onabotulinumtoxinA service

Learning Objectives

OnabotulinumtoxinA clinical data

Chapter 1: What is onabotulinumtoxinA?

  • Gain a background on onabotulinumtoxinA: the molecule, and its applications in a variety of disease indications

Chapter 2: How does onabotulinumtoxinAwork in the bladder?

  • Gain a detailed understanding of how onabotulinumtoxinA works in the bladder
  • Understand the sensorimotor action of onabotulinumtoxinA in OAB and NDO

Chapter 3: Evidence for onabotulinumtoxinA in OAB

  • Understand the efficacy and safety profile of onabotulinumtoxinA for OAB
  • Understand the impact on QoL for patients with OAB who receive onabotulinumtoxinA injections

Chapter 4: Evidence for onabotulinumtoxinA in NDO

  • Understand the efficacy and safety profile of onabotulinumtoxinA for NDO
  • Understand the QoL impact of onabotulinumtoxinA for patients with NDO

OnabotulinumtoxinA in practice

Chapter 1: Practical considerations before treatment

  • Explore who is eligible for onabotulinumtoxinA therapy
  • Understand the equipment needed and preparations required before treating a patient with onabotulinumtoxinA
  • Understand other practical considerations that you need to have addressed before administering onabotulinumtoxinA

Chapter 2: Administration in OAB

  • Understand all procedural considerations for onabotulinumtoxinA administration in OAB, whether you are a first time or repeat injector conducting your work in an office or a theater

Chapter 3: Administration in NDT

  • Understand how to prepare onabotulinumtoxinA using two 100 Unit vials for NDO
  • Understand how to prepare onabotulinumtoxinA using one 200 Unit vial for NDO

Chapter 4: Aftercare and re-treatment

  • Understand what is required post-treatment in order to ensure your patients receive the best possible care
  • Review when re-treatment should be considered according to clinical trial data

Chapter 5: A fully informed patient

  • Learn how to appropriately educate patients about onabotulinumtoxinA: the product and the procedure
  • Learn ways of allaying patients' potential anxieties and misconceptions about onabotulinumtoxinA
  • Understand how to guide patients' expectations in terms of efficacy and potential side effects

Chapter 6: Setting up an onabotulinumtoxinA service

  • Understand the practical considerations for setting up an onabotulinumtoxinA service
  • Understand the steps required to secure funding for your service
  • Understand how to develop an implementation plan for your service

Learning Modules

Module 1: OnabotulinumtoxinA clinical data

  • Chapter 1: What is onabotulinumtoxinA?
  • Chapter 2: How does onabotulinumtoxinAwork in the bladder?
  • Chapter 3: Evidence for onabotulinumtoxinA in OAB
  • Chapter 4: Evidence for onabotulinumtoxinA in NDO

Module 2: OnabotulinumtoxinA in practice

  • Chapter 1: Practical considerations before treatment
  • Chapter 2: Administration in OAB
  • Chapter 3: Administration in NDT
  • Chapter 4: Aftercare and re-treatment
  • Chapter 5: A fully informed patient
  • Chapter 6: Setting up an onabotulinumtoxinA service

At a glance

  • Last updated on: Jan 1, 2022
  • Publication date: March 2015
  • Available languages: English
  • Duration: Approx. 120 minutes
  • Target group: junior or senior urologists
  • Topic: OAB and NDO
  • CME: 2 European CME credits (ECMEC)

Contact our organiser

European School of Urology

Email:  educationonline@uroweb.org

Share this event

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer